Johnson & Johnson

NYSE:JNJ   12:09:17 PM EDT
-0.96 (-0.59%)

Janssen Gets FDA Approval For Schizophrenia Treatment Invega Hafyera

Published: 09/01/2021 12:06 GMT
Johnson & Johnson (JNJ) - Janssen Announces U.S. FDA Approval of Invega Hafyera™ (6-month Paliperidone Palmitate), First and Only Twice-yearly Treatment for Adults With Schizophrenia.
Janssen - Phase 3 Non-inferiority Study Results Showed Over 92% of Participants Were Relapse-free at 12 Months.